Assessment of the Drug Interaction Potential of Ertugliflozin With Sitagliptin, Metformin, Glimepiride, or Simvastatin in Healthy Subjects

Ertugliflozin, a sodium‐glucose cotransporter 2 inhibitor for the treatment of adults with type 2 diabetes mellitus, is expected to be coadministered with sitagliptin, metformin, glimepiride, and/or simvastatin. Four separate open‐label, randomized, single‐dose, crossover studies were conducted in h...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Clin Pharmacol Drug Dev
Glavni autori: Dawra, Vikas Kumar, Cutler, David L., Zhou, Susan, Krishna, Rajesh, Shi, Haihong, Liang, Yali, Alvey, Christine, Hickman, Anne, Saur, Didier, Terra, Steven G., Sahasrabudhe, Vaishali
Format: Artigo
Jezik:Inglês
Izdano: John Wiley and Sons Inc. 2018
Teme:
Articles
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6586154/
https://ncbi.nlm.nih.gov/pubmed/29786959
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cpdd.472
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items